RaDes GmbH, Schnackenburgallee 114, 22525 Hamburg, Germany.
Boehringer Ingelheim GmbH & Co KG, Innovation Unit, Birkendorfer Straße 65, 88400 Biberach, Germany.
J Chromatogr B Analyt Technol Biomed Life Sci. 2020 Nov 10;1157:122287. doi: 10.1016/j.jchromb.2020.122287. Epub 2020 Jul 31.
Polysorbates are widely used as non-ionic surfactant in biopharmaceutical formulations. Recently, the degradation of polysorbate moved into the focus of attention, because in several published studies it was described, that stability issues in polysorbate containing formulations were observed leading to the formation and appearance of sub-visible and visible particles. For this reason, monitoring of polysorbate and its degradation products is of importance throughout the development of parenterals. The aim of the study was to develop a method for the selective marker-based quantification of adequate polysorbate 20 components of interest without the need to apply derivatization or complex detection techniques. A single quadrupole mass (QDa) detector was used coupled to an ultra-high performance liquid chromatography (UPLC) system. Method development was based on a reversed phase-high performance liquid chromatography assay coupled to a charged aerosol detector (RP-HPLC CAD). Instead of a charged aerosol detector (CAD) a QDa detector was used in order to significantly improve the selectivity. The focus of this study is the development of the QDa based method for the analysis of polysorbate 20. Modifications of the mobile phase and the type of chromatography column allowed the separation of several components of polysorbate 20 from polar non-esterified to apolar higher order species. In addition, a multitude of components could be quantified by their individual m/z values. The peak assignment identified 676 compounds which originated from polysorbate 20. Some of these were selected and defined as marker components. It was shown that the developed method is capable to determine polysorbate 20 in different biopharmaceutical formulations. The proposed assay is based on a smart sample preparation as well as a unique calibration procedure that make the determination of several selected components achievable. Furthermore, it was successfully demonstrated that the analytical procedure is valid to reliably quantify several polysorbate 20 components at its 100% level (corresponds to 0.4 mg/mL intact polysorbate 20) and even at lower concentrations that occur e.g. in case of polysorbate 20 degradation. In conclusion, the method is beneficial to determine selected polysorbate 20 species during formulation development of biopharmaceuticals as well as during stability testing and trouble shooting.
聚山梨酯是生物制药制剂中广泛使用的非离子表面活性剂。最近,聚山梨酯的降解问题引起了人们的关注,因为在一些已发表的研究中描述了在含有聚山梨酯的制剂中观察到稳定性问题,导致亚可见和可见颗粒的形成和出现。因此,在开发注射剂的整个过程中,监测聚山梨酯及其降解产物非常重要。本研究的目的是开发一种选择性标记物定量分析适当聚山梨酯 20 感兴趣成分的方法,而无需应用衍生化或复杂的检测技术。使用单四极杆质量 (QDa) 检测器与超高效液相色谱 (UPLC) 系统耦合。方法开发基于反相高效液相色谱测定法与带电气溶胶检测器 (RP-HPLC CAD) 耦合。为了显著提高选择性,本研究使用 QDa 检测器代替带电气溶胶检测器 (CAD)。本研究的重点是开发基于 QDa 的聚山梨酯 20 分析方法。对流动相和色谱柱类型的修改允许从极性非酯化到非极性更高阶物质分离出聚山梨酯 20 的几个成分。此外,还可以通过其各自的 m/z 值对多种成分进行定量。峰分配确定了源自聚山梨酯 20 的 676 种化合物。选择并定义了其中一些作为标记成分。结果表明,所开发的方法能够在不同的生物制药制剂中测定聚山梨酯 20。所提出的测定法基于智能样品制备以及独特的校准程序,使多个选定成分的测定成为可能。此外,成功证明了分析程序可用于可靠地定量几种聚山梨酯 20 成分的 100%水平(相当于 0.4mg/mL 完整聚山梨酯 20),甚至在较低浓度下也能定量,例如在聚山梨酯 20 降解的情况下。总之,该方法有利于在生物制药制剂的开发过程中以及在稳定性测试和故障排除过程中确定选定的聚山梨酯 20 物种。